BACIL PHARMA LTD.

Bacil Pharma Limited is classified under pharmaceuticals and biotechnology, but according to its audited FY26 results it currently has no revenue from operations. The full-year FY26 'total income from operations' of Rs 123.52 lakh (FY25: Rs 198.50 lakh) came entirely from other income, not from any product or service sales, and the statutory auditor flagged a complete revenue collapse and material uncertainty on the going-concern assumption. The only concrete business activity visible is the incorporation on 28 July 2026 of a wholly-owned subsidiary named Bacil Research and Development Private Limited, which is intended to carry out research and development work for the parent. Net profit after tax of Rs 155.55 lakh for FY26 was driven by a Rs 56.53 lakh deferred tax credit rather than operating earnings; profit before tax was actually a Rs 3.89 lakh loss. Total assets stood at Rs 2,739.26 lakh, with cash and cash equivalents down sharply from Rs 285.73 lakh to Rs 56.85 lakh and borrowings rising from Rs 16.39 lakh to Rs 1,639 lakh. The board has approved raising up to Rs 50 crore through a Rights Issue (with authorised share capital to rise by Rs 45 crore to Rs 65 crore) to fund what management describes as future operations.